The University of Osaka · Medicine
Professor Hirofumi Yamamoto's research lab specializes in molecular oncology and cancer biology, with a focus on identifying key molecular drivers of tumor progression and therapy resistance. The lab investigates oncogenes such as KRAS and signaling pathways involving survivin and PLOD2, exploring their roles in cancer cell survival, proliferation, and response to treatment. Using integrative approaches including molecular profiling, functional genomics, and translational studies, the lab aims to uncover novel therapeutic targets and prognostic biomarkers, particularly in hepatocellular carcinoma (HCC) and gastrointestinal cancers. Their work emphasizes the clinical relevance of these molecules in improving patient outcomes through early detection and targeted therapy.
Figures are computed from collected data and may differ slightly.
PSVT is a more frequent complication of laparoscopic splenectomy than previously reported but can be treated safely following early detection by CT with contrast.
Survivin has multiple functions including cytoprotection, inhibition of cell death, and cell-cycle regulation, especially at the mitotic process stage, all of which favor cancer survival. Many studies on clinical specimens have shown that survivin expression is invariably up-regulated in human cancers and is associated with resistance to chemotherapy or radiation therapy, and linked to poor prognosis, suggesting that cancer cells survive with survivin. It is also reported that survivin inhibitio
KRAS mutations are a major cause of drug resistance to molecular-targeted therapies. Aberrant epidermal growth factor receptor (EGFR) signaling may cause dysregulation of microRNA (miRNA) and gene regulatory networks, which leads to cancer initiation and progression. To address the functional relevance of miRNAs in mutant KRAS cancers, we transfected exogenous KRAS(G12V) into human embryonic kidney 293 and MRC5 cells with wild-type KRAS and BRAF genes, and we comprehensively profiled the dysregu
PLOD2 is a potential novel prognostic factor for HCC patients following surgery.
Open papers in the app to read, cite, and organize with AI.
